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1. Introduction 
Kidney transplantation is considered the best treatment for end stage renal failure (ESRF) 
with longer life expectancy and superior quality of life compared to dialysis therapy [1-3]. 
However, a major constraint to transplantation is the lack of suitable organ donors. To 
increase the number of available organs there has been an incentive to use ‘marginal’ donors 
such as donation after cardiac death (DCD) and expanded criteria donors (ECD), in addition 
to kidneys from the traditional living and deceased donors [4,5]. Although an important 
source of organs for transplantation, once transplanted a significant proportion of these 
kidneys have early graft dysfunction. 
There are many attributing factors that influence the outcome of the transplanted graft. 
Donor and recipient age, creatinine clearance, history of hypertension, poor human 
leukocyte antigen (HLA) matching, cause of death, ethnicity, the cold ischaemic (CI) time 
and in the case of DCD donors the warm ischaemic insult have all been described as major 
determinants of graft function and graft survival [6]. The CI time is perhaps the only 
modifiable factor that significantly affects graft outcome.  
Since the 1970s organ preservation has relied on hypothermic conditions to allow an organ 
to be preserved outside the body from the time of retrieval until transplantation. This allows 
the organ to be allocated nationally, to the most suitable and immunologically matched 
recipient. Nonetheless, hypothermic preservation has its limitations and viability cannot be 
sustained for an indefinite period of time. Hypothermic preservation has been described as 
‘a compromise between the benefits and detriments of cooling’ [7].  
2. Standard criteria donor (SCD) 
Deceased organ donors fall into three categories. A standard criteria donor is a deceased 
donor who is declared brain dead after a stroke or other brain injury. Brain death means that 
there is the irreversible loss of function of the brain.  
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3. Donation after cardiac death (DCD) donor 
Donation after cardiac death donors (DCD) are donors from which the organs are retrieved 
after the cessation of circulation due to a cardiac arrest. These organs are regarded as 
marginal organs due to the warm ischaemic (WI) insult that they receive before the onset of 
preservation. This WI interval causes a degree of injury that can lead to irreversible damage, 
resulting in an unfavourable outcome after transplantation. Four classifications of DCD 
donors have been categorised depending on the circumstances of death and when the 
organs are retrieved [8,9] (Table 1).  
 
Category Definition Type 
1 Dead on arrival Uncontrolled 
2 Unsuccessful resuscitation Uncontrolled 
3 Awaiting cardiac arrest Controlled 
4 Cardiac arrest while brain death Controlled/uncontrolled 
Table 1. Maastricht categories of donation after cardiac death donors. 
Maastricht type 1 and 2 donors are patients who have died suddenly from a cardiac event or 
trauma and therefore are usually based in the Accident & Emergency department. After a 
failed resuscitation, the patient is pronounced dead and a 5 minute ‘hands off’ period 
allowed to lapse. The organs are perfused in-situ through aortic cannulas inserted through 
the femoral artery [10].  
Maastricht type 3 and 4 are patients who are based on an intensive care unit after a severe 
brain injury. The patient does not meet the criteria for brain stem death and will maintain 
spontaneous ventilation. Under controlled conditions with no possibility of recovery 
withdrawal of treatment is planned. After the cessation of the heartbeat the patient is 
transferred to the operating theatre and the kidneys retrieved after in-situ cooling. In the 
uncontrolled situation an unexpected cardiac arrest follows brain stem death. The WI time is 
usually within the region of 15 minutes for controlled donors but can be considerably longer 
in the uncontrolled situation. 
4. Expanded criteria donors (ECD) 
Expanded criteria donors (ECD) are defined as any brain dead donor aged ≥ 60 years or over 
50 years with ≥ 2 of the following conditions; Hypertension, terminal serum creatinine equal 
or greater than 132µmol/L or death resulting from an intracranial haemorrhage.  
5. Cold ischaemic injury 
Hypothermic preservation is based on the principle that cooling an organ inhibits the 
enzymatic processes. There is a 2-3 fold decrease in metabolism for every 10°C reduction in 
temperature [11,12]. This slows the depletion of adenosine triphosphate (ATP) and also 
inhibits the degrading processes (phospholipid hydrolysis). Nonetheless, under 
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hypothermic conditions the metabolic rate remains at about 10% and therefore over time, 
the hypoxic conditions cause substantial injury [12] this is termed CI injury.  
The depletion of ATP due to the inhibition of oxidative metabolism increases levels of 
adenosine, inosine and hypoxanthine within the cell leading to the formation of lactic acid 
[13]. This lowers the intracellular pH causing lysosomal instability and the activation of lytic 
enzymes [14,15]. The depletion of ATP also reduces a large number of cellular processes. 
Inactivation of the Na+/K+ ATPase pump allows the accumulation of calcium, sodium and 
water within the cell causing cellular swelling [15]. The binding of transition metals such as 
iron to their carrier proteins (transferrin, ferritin) is also inhibited which increases the 
intracellular concentration of free iron [16,17]. This is a strong catalyst for the generation of 
oxygen free radicals which promotes the production of other free radicals [14]. The impact 
of CI injury is evident immediately after transplantation when oxygenated blood is re-
introduced into the kidney. The downstream effects of ischaemia reperfusion (I/R) injury 
results in tubular and vascular damage with the impairment of blood flow to the kidney and 
reduced urine output after transplantation. The kidney can withstand CI times up to 48 
hours. Nonetheless, attempts have been made to reduce CI injury and on average the CI 
time now falls below 24 hours in most transplant centres.  
6. Impact 
6.1. Delayed graft function 
Renal graft function after transplantation is typically measured as incidence of delayed graft 
function (DGF). There are several definitions of DGF however the majority of centres define 
DGF as the requirement for dialysis within the first week after transplantation. The 
diagnosis is based on low urine output, slow decline in serum creatinine levels and 
increased metabolic instability. Acute tubular injury, otherwise termed acute tubular 
necrosis (ATN) caused by ischaemic injury is the main cause of DGF after transplantation 
[18]. DGF is associated with complications such as acute rejection, increased fibrosis and the 
risk of poorer long term graft survival. It also has a significant economic cost, can complicate 
patient treatment and prolong hospital stay [19]. Rates of DGF typically range from 5 to 40% 
in deceased donor kidney transplants [20]. Rates of DGF in live donor transplantation are 
significantly less (2-5%) due to the short CI time and healthy younger donors [21]. 
Many experimental studies have shown that the duration of CI directly influences graft 
function. Several studies suggest that even after 6 hours of CI, significant injury occurs 
[22,23]. Clinically, the CI time has been clearly shown as an independent risk factor for DGF 
and reducing the CI time can reduce the incidence of DGF. In an analysis of a series of DBD 
transplants the risk of DGF was found to increase by 23% for every 6 hours of CI [24] and 
Locke et al found that limiting the CI time to less than 12 hours reduced the risk of DGF by 
15% [25]. Other studies have shown that the risk of DGF is increased by 3.3 and 4.4 fold by 
increasing the CI time by 5 and 10 hours [26]. 
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6.2. Graft survival 
The CI time is regarded as an independent risk factor for DGF and DGF is associated with 
reduced graft survival [27,28]. However, recent evidence suggests that the association of CI 
time and DGF may have less of an impact on graft survival than previously thought. A 
multicentre analysis of kidney preservation found that only when the preservation period 
exceeded 18 hours was the CI time associated with reduced graft survival [29]. A large 
analysis of registry data of paired deceased donor kidneys found that DGF induced by CI 
injury had a limited impact on the long term outcome. Nonetheless, in other studies the CI 
time has been found to independently influence graft survival even in live donor 
transplantation and in young deceased donors [30,31]. 
The disparity between DGF and survival is perhaps due to the lack of sensitivity of DGF in 
determining the severity of kidney injury. DGF is a simple and standard method of reporting 
early graft dysfunction. However, dialysis within the first week after transplantation can be 
used to correct metabolic instability without the presence of significant kidney injury. As such, 
it is difficult to determine the impact of DGF. DGF due to CI can be reversible and therefore 
have no effect on long term outcome [32]. However, in severe cases, DGF can lead to 
incomplete recovery and reduced graft survival due to the loss of nephron mass [33]. Giral-
Classe et al reported that rather than the incidence of DGF, the duration of DGF was the 
important factor with DGF over six days associated with reduced long term graft survival [34]. 
More recently, urinary biomarkers have been used to determine the severity of acute kidney 
injury with cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-
18] and kidney injury molecule-1 (KIM-1) emerging as the most reliable and sensitive markers 
of injury [35-37]. Although, not readily used as a diagnostic tool in clinical practice, they may 
be applied more frequently in the future.  
7. Acute rejection 
Acute rejection (AR) following renal transplantation can be split into two categories, cell 
mediated rejection and antibody mediated rejection (also termed vascular rejection). Acute 
cellular rejection is the more common of the two types and with the introduction of modern 
immunosuppressive agents rates have dropped from 50% a decade ago to 15-20% today. 
The typical stimulus for cellular rejection is the presence of so-called ‘passenger leucocytes’ 
which are immune cells carried within the blood vessels and tissues of the donor organ. 
Following transplantation they are exposed to the recipient immune system which 
recognises them as foreign and results in activation of host lymphocytes which attack the 
donor kidney. Antibody mediated rejection is less common and usually more severe and if 
left untreated can rapidly destroy the graft.  
Acute rejection is an important factor in early outcomes of transplantation and is closely 
associated with delayed graft function (DGF) [38-41]. The precise link between DGF, acute 
rejection and CI time is difficult to fully elucidate. Prolonged CI has been shown to be one of 
the main risk factors for DGF and DGF is an independent risk factor for AR [42]. However, 
DGF is a result of a number of factors and it is over simplistic to ascribe acute rejection to 
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just one of those factors. Nonetheless there is evidence that the CI time, alongside other 
factors, including duration of dialysis, number of HLA mismatches, panel reactive 
antibodies more than 5% are independent predictors of AR. A large retrospective analysis of 
611 transplants demonstrated that CI time was the strongest predictor of DGF [42]. The risk 
of DGF increased from 9.6% with 12 hours CI time to 21.5% with 24 hours CI time. In the 
same analysis the risk of AR was increased by 4% for each additional hour of CI time and 
the risk of rejection in patients receiving kidneys with less than 24 hours CI time was 14.1% 
compared to 29.3% in kidneys with greater than 24 hours CI time. Furthermore, death-
censored graft survival is significantly reduced in patients in whom AR complicates DGF. In 
addition CI duration of greater than 24 hours has a significantly reduced death-censored 
graft survival in comparison with durations of less than 24 hours [42].  
8. Donor specific effects 
Kidneys from DCD and ECD donors commonly present with high rates of DGF compared 
to SCD and live donors. [43]. DGF typically ranges from 22% to 84% in DCD kidneys 
compared to 14% to 40% in DBD donors [25, 44-47]. Evidence suggests that the outcome of 
kidneys from uncontrolled DCDs is poorer when compared to the controlled DCDs with 
significantly higher rates of DGF, as a response to the longer duration of warm ischaemic 
(WI) injury under the uncontrolled situation [48].  
Kidneys from ECD have a 70% increased risk of graft loss and higher rates of DGF 
[25,49,50]. The prognosis is even poorer in DCD kidneys from older donors (over 50 years) 
with the risk of graft failure rising to 80% [25].  
In addition to DGF, a small but significant proportion of kidneys from DCD donors also have 
primary non function (PNF) with rates reported to range from 4 to 19% amongst transplant 
centres over the last 30 years [51,52]. PNF is particularly detrimental as the patient is exposed 
to surgery and immunosuppressive therapies without benefit. Furthermore, they may become 
sensitized to donor antigens, reducing the opportunity for future transplants.  
The WI insult in DCD kidneys and the reduced capacity of kidneys from ECDs to recover and 
regenerate are certainly major contributing factors for early graft dysfunction. Experimental 
evidence suggests that the combined effect of WI and CI injury exacerbates the injury during 
reperfusion and the duration of CI has been found to have a strong influence on graft outcome 
[53]. However, the impact of CI in clinical transplantation is again varied. It appears that as in 
SCDs, long term graft survival is not necessarily affected by DGF and CI not necessarily an 
independent predictor of graft survival. Recent evidence from clinical DCD and DBD 
programmes have reported similar rates of graft survival after 5 and 10 years [45,54-57]. In a 
series of 112 uncontrolled DCD kidneys, DGF rates were 84% compared to 22% in DBD donors 
[54]. Nevertheless, the graft survival rates were similar in both groups of patients, 69.3% 
versus 75.5% at 5 years and 50.3% versus 57.9% at 10 years, respectively. The link between WI, 
CI and graft survival is not well documented. However, it appears that prolonged CI after a 
period WI may not be as detrimental to graft survival as previously thought and that kidneys 
can recover from ischaemic injury with no long term effects [58]. 
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9. Preservation techniques 
Organ preservation was first introduced into clinical transplantation in the 1960s. Until this 
time without proper preservation conditions, kidneys were transplanted as soon as possible 
after retrieval to minimize the injury. It was then recognized that in order to improve the 
outcome of transplantation, better methods of preservation were required. Experimental 
studies in the 1950s by Lapchinsky [59] in the Soviet Union and the early work by Carrel 
and Lindbergh, showed that ischaemic injury could be minimized by reducing the 
temperature [60]. In 1963, Calne et al used the concept of hypothermic temperatures to 
extend the preservation time and successfully transplant canine kidneys after 12 hours of 
storage [61]. This led to the application and development of preservation techniques and 
solutions that are used today. 
10. Static cold storage 
Static cold storage (CS) is undoubtedly the simplest and most widely utilised method of 
hypothermic preservation. The kidney is flushed with cold preservation solution to remove 
the blood and cool the organ. The kidney is then stored in solution surrounded by crushed ice. 
Preservation solutions have been designed to counteract the detrimental effects of CI injury. 
There are a number of commercially available preservation solution, which all contain the 
same basic formula. This includes an impermeant to minimise swelling and provide stability 
to the ultra-structure of the cell. A buffer and a balanced electrolyte composition with either a 
high or low Na+ / K+ ratio to prevent the build up of intracellular acidosis and further 
minimize cellular swelling (Table 2). Solutions with a high potassium concentration are 
classified as intracellular and those with a high sodium concentration extracellular solutions. 
 
Components  
Impermeants glucose, lactobionate, mannitol, raffinose, sucrose 
Colloid hydroxyethyl starch (HES), polyethylene glycol (PEG) 
Buffers citrate, histidine, phosphate 
Electrolytes calcium, chloride, magnesium, magnesium sulphate, potassium, sodium 
Anti-oxidants allopurinol, glutathione, mannitol, trytophan 
Additives adenosine, glutamic acid, ketoglutarate 
Table 2. Components commonly used in preservation solutions 
11. Static cold storage solutions 
11.1. Euro Collins 
In 1969 Geoffrey Collins developed the first acellular preservation solution (Collins solution) 
containing a high concentration of potassium and glucose [62]. Collins solution was later 
modified omitting some of the ingredients such as magnesium, heparin, procain and replacing 
glucose with mannitol to provide better osmotic properties and lower the viscosity [63-65]. It 
was renamed Euro Collins solution and was widely used amongst the transplant community.  
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11.2. Hyperosmolar citrate 
Hyperosmolar citrate (HOC) or more commonly known as Soltran or Marshall’s solution 
was first developed in the 1970s as an alternative to Collins solution [66,67]. It is has a high 
potassium content and contains basic ingredients using citrate as a buffer. Its hypertonicity 
is designed to prevent fluid entry into cells. It is a relatively inexpensive, non-viscose 
solution that is still commonly used throughout the UK in kidney transplantation. It is not 
recommended for DCD or marginal kidneys despite the fact that there is little evidence to 
support this view.  
12. University of Wisconsin solution 
University of Wisconsin (UW) solution has a high potassium concentration to maintain the 
intracellular ionic balance. It is a more complex preservation solution compared to Euro 
Collin and HOC, containing trisaccharide raffinose and the anion lactobionate as osmotic 
impermeants, a phosphate buffer, anti-oxidants (glutathione) to scavenge oxygen free 
radicals, allopurinol to block the activity of xanthine oxidase and adenosine, an ATP 
precursor. It also contains the colloid hydroxyethyl starch (HES), to prevent cellular swelling 
[68]. However, it is debatable whether this is it necessary in a static storage solution and 
there is some evidence showing that HES can increase tubular damage and cause red blood 
cell aggregation. Another potential disadvantage of UW solution is the high concentrations 
of potassium. Although thought important in the prevention of the build up of intracellular 
calcium, potassium can induce cellular depolarization, reduce cellular 5’-triphosphate 
content and activate voltage-dependent channels, such as calcium channels [69]. 
Nonetheless, due to its composition UW solution had, and still has, a significant advantage 
over other preservation solutions enabling kidneys to be stored for longer periods with 
better function and less histological injury after transplantation. It is still considered the 
‘gold standard’ preservation solution today.  
13. Histidine-Tryptophan-Ketoglutarate (HTK) 
HTK was originally developed as a cardioplegic solution but because of its low viscosity 
was quickly adopted for clinical preservation of the kidney, pancreas and liver [70-72]. It is 
an extracellular solution and uses the impermeant mannitol and histidine as a buffer. It also 
contains 2 amino acids, tryptophan, to stabilize cellular membranes and prevent oxidant 
damage and ketoglutararate, a substrate to support anaerobic metabolism. Recent concerns 
have been raised regarding its use for ECD and DCD kidneys or for kidneys with prolonged 
storage times [73]. Some clinical studies have associated its use with the increased risk of 
PNF and early graft loss [74]. Nonetheless, it is a popular preservation solution widely used 
throughout Europe and the UK. 
14. Celsior solution 
Celsior is an extracellular solution and was initially designed for heart transplantation. It 
contains a high sodium concentration with histidine as a buffer, lactobionate and mannitol 
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to prevent oedema and glutathione as an antioxidant. The solution has proved beneficial in 
heart, liver, pancreas and in kidney transplantation [75-78].  
15. Outcome 
An abundance of experimental studies have investigated the efficacy of one solution over 
another with the majority of studies labelling UW solution as the most superior. However, 
clinically the evidence is sparse. UW, HTK and Celsior appear to be the better preservation 
solutions with little difference in rates of DGF between the solutions its usage. Euro Collin 
solution is not widely used and is regarded as inferior with the suggestion of increasing the 
risk of DGF [79]. The outcome of individual preservation solutions is more apparent when the 
CI time is extended beyond 24 hours with UW fairing significantly better than other solutions.  
16. Hypothermic machine perfusion 
Since the introduction of CS techniques in the 1970s there has been much debate about 
whether CS or hypothermic machine perfusion (HMP) is the best method of kidney 
preservation. Undoubtedly, the simplicity of CS has a significant advantage over HMP. 
However, HMP is it thought to be a better method of preservation in that it allows a 
continual flush of the microcirculation, prevents the accumulation of waste products, 
sustains a higher metabolic rate, protects against depolarization of the endothelial cell 
membrane and reduces free radical formation [80]. 
Folkert O Belzer was the first to develop a portable HMP system [81,82] in the 1960s. 
However, with the introduction and success of CS in the 1970s there was little development 
of this technique in subsequent decades. Nonetheless, with the increasing use of DCD and 
ECD kidneys over the last decade, there has been renewed interest into the use of HMP. 
New simpler and portable systems have been developed such as the Lifeport Kidney 
Transporter (Organ Recovery System, US) which has encouraged the use of this technology. 
Many experimental studies have found HMP to improve preservation [7,12] and the quality 
of the kidney. The largest multicentre clinical trial conducted in Europe comparing CS and 
HMP in deceased donors found that HMP reduced the risk of DGF compared to CS 
(adjusted odds ratio, 0.57; P=0.01] and improved 1 and 3 year graft survival [83,84]. 
Although the overall rate of DGF was only reduced by 6%.  
The evidence suggests that HMP may be more beneficial in reducing DGF rates in marginal 
kidneys. In a sub-analysis of 82 pairs of DCD kidneys from the European trial, the DGF rate 
in the HMP group was 53.7% compared to 69.5% in kidneys that were statically stored [85]. 
However, there was no significant difference in graft survival at 1 or 3 years. In a further 
sub-analysis of ECD donors in this trial, HMP reduced rates of DGF from 29.7% to 22% and 
also improved 1 and 3 year graft survival in ECD kidneys [84,86]. In contrast to this support 
for HMP, a multicentre UK trial found no beneficial effects of HMP. 45 pairs of controlled 
DCD kidneys were randomized to HMP or CS [87]. The DGF rates were 58% vs 56% in the 
HMP and CS groups respectively. However, this trial has been criticised for the sequential 
design and the small number of patients [88]. 
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HMP techniques are still open to criticism with the suggestion of increased endothelial 
injury, as found in a recent study of porcine livers [89], risk of trauma to the vessels and the 
question of cost effectiveness compared to static storage techniques [90]. Nonetheless, it 
appears that HMP may hold a significant advantage in reducing CI injury compared to CS 
techniques. The experimental evidence is strong and there is a growing abundance of 
evidence from clinical studies to suggest an advantage. However, the evidence is not 
conclusive and there is a need for more clinical trials to determine the superior method of 
preservation. 
17. Normothermic machine perfusion 
Maintaining an organ under normothermic conditions is an alternative technique of 
preservation. Continuous perfusion of the kidney at warmer temperatures with the delivery 
of nutrients and oxygen has the advantage of avoiding hypothermic injury and hypoxia. In 
addition, it also may aid recovery and prevent further injury. 
Early attempts at normothermic preservation were generally unsuccessful due to the 
inability to maintain cellular integrity and support renal metabolism. However, advances 
have been made over the last few decades with the use of technology borrowed from 
cardiac surgery. The development of less traumatic perfusion pumps and the recognition of 
the necessity for the delivery of nutrients and oxygen to achieve successful perfusion has 
made normothermic preservation a realistic contender in clinical transplantation.  
Normothermic perfusion can be applied in various ways. The concept of extracorporeal 
membrane oxygenation (ECMO) to maintain extracorporeal circulation at normal room or 
body temperature with hyperoxygenated blood can be used to maintain tissue perfusion 
after the heart has stopped. Normothermic recirculation has proved beneficial in the 
retrieval of hearts, lungs and abdominal organs. Valero et al assessed the effects of 
implementing this technique in clinical practice in small group of DCD donors [91]. 
Circulation was maintained for 60 minutes before total body cooling. The incidence of DGF 
and PNF was reduced after normothermic recirculation compared to standard in situ or total 
body cooling. Gravel et al described a DGF rate of 11% in controlled DCD donors [92] and 
Lee et al found similar 5 year graft survival rates to DBD and living donors [93]. Maintaining 
circulation before retrieval is thought to condition the organs by up-regulating adenosine 
receptors which may protect against preservation injury [91]. Reznik et al, recently reported 
the application of extracorporeal normothermic recirculation in uncontrolled DCD donors 
using leukocyte depleted blood [94,95]. Initial graft function was achieved in 6 out of the 16 
patients. In the kidney, more evidence is needed to determine how normothermic 
recirculation before retrieval correlates with early and longer term graft function.  
In consideration of the logistical problems of prolonged preservation a great deal of research 
has focused on using normothermic preservation in combination with hypothermic 
techniques. Experimentally, intermediate periods of normothermic preservation have been 
used to restored energy metabolism with replenishment of adenosine levels, effectively 
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‘resuscitating’ the organ and retaining viability compared to kidneys stored under 
hypothermic conditions [96,97]. 
Brasile et al found that a period of warm ex-vivo perfusion at the end of the preservation 
period could resuscitate the kidney after warm and cold ischaemic injury [98,99]. More 
prolonged normothermic preservation periods have also been more beneficial than 
hypothermic techniques [100,101]. The only report of a normothermic kidney perfusion 
technique in clinical practice is by Hosgood and Nicholson [102]. In this single case report of 
a short period of normothermic perfusion of a marginal kidney with an oxygenated packed 
red blood cell based solution, the recipient had immediate graft function compared to DGF 
in the recipient of the paired CS kidney. Further results of the ongoing series at Leicester are 
awaited. Nonetheless, despite the potential benefits, normothermic preservation is 
logistically difficult to carry out requiring technical support and expensive perfusion 
systems.  
18. Biomarkers 
Measuring the amount of ischaemic injury during preservation would be advantageous as 
the quality of the kidney could be assessed and a decision made upon its viability. This 
would be particularly beneficial for marginal kidneys to reduce the likelihood of PNF. 
Viability is normally assessed by numerous factors including donor history, duration of 
cardiac arrest, the quality of in-situ perfusion, CI interval and visual inspection of the 
kidney. Ultimately this relies on the judgement of an experienced surgeon. To avoid PNF, 
surgeons are typically cautious and therefore many kidneys are deemed unsuitable for 
transplantation and are discarded [57]. HMP has been used to assess viability. Two aspects 
can be measured; Firstly, the continuous recirculation of preservation solution through the 
kidney allows the perfusate flow to be measured and intra-renal resistance can be 
calculated. Secondly, the perfusate can be sampled to measure cellular injury.  
Clinically, the perfusion flow index (PFI) has been used as a measure of flow and resistance 
[103,104]. This is based on a minimum flow being obtained for a given pressure. The 
Transplant Group at Newcastle, UK recommend that a PFI of greater than 
0.6ml/min/mmHg/100 gram of kidney is needed for a kidney to be deemed suitable for 
transplantation [105]. However, the ability of these parameters to predict DGF or PNF in 
clinical practice is limited. Jochman et al recently reported that although renal resistance 
(RR) at the end of HMP was an independent risk factor for DGF and 1 year graft survival, it 
had a low predictive power and could not be relied on as a sole measure of viability [106]. 
This is in agreement with other small clinical studies by Sonnenday [107] and Guarrera [108] 
et al that showed that kidneys with poor perfusion parameters had a similar outcome to 
those with good parameters.  
Viability can also be measured by sampling the perfusate for biomarkers of cellular injury. 
Markers such as redox free iron, glutathione S-transferase (GST), total glutathione S-
transferase (tGST), lactate dehydrogenase (LDH), N-acetyl-β-D-glucosaminidase (NAG), 
heart-type fatty acid binding protein (H-FABP) and alanine aminopeptidase (Ala-AP) have 
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all been used to determine injury [104-106,109]. There is little information on their predictive 
value. However, Jochman et al recently published the results from the European HMP trial 
in which perfusate samples were taken for the assessment of biomarkers at the end of HMP 
[106]. GST, NAG, and H-FABP were found to be independent predictors for DGF but not for 
graft survival in the first year after transplantation. LDH, ASAT, and Ala-AP were found to 
have no predictive potential for post transplant outcome. Furthermore, the biomarkers did 
not correlate with intra renal resistance. The evidence suggests that viability assessment 
during HMP cannot be used independently but may be used collectively with the kidney 
characteristics and donor demographics to determine the suitability of a kidney for 
transplantation. 
Normothermic preservation techniques may hold more promise in the assessment of 
viability compared to HMP techniques. During normothermic perfusion renal function and 
metabolism are restored. In experimental models, low levels of blood flow, reduced renal 
function and low oxygen consumption have been associated with increased ischaemic 
injury. Furthermore, these functional measures could be combined with injury biomarkers 
to assess the quality of the kidney. 
19. Experimental studies 
19.1. Oxygenation 
There is a growing body of evidence in support of recovering ischaemically damaged organs 
with oxygenated preservation techniques at low temperatures. Historically, oxygenation 
was considered an essential component of hypothermic kidney preservation in order to 
support mitochondrial resynthesis of ATP and to delay the injury process. However, with 
the introduction of the modern day preservation solutions, and the rapid adoption of simple 
CS techniques, oxygen was not thought to be a vital ingredient and as such is not commonly 
applied in the clinical setting. Various techniques have been used to apply oxygen under CS 
and HMP conditions. 
Retrograde oxygen persufflation is a simple technique whereby filtered and humidified 
oxygen is bubbled directly through the renal vasculature during CS. The gas is then allowed 
to escape through small perforations in the surface of the organ. Reports of its application 
date back to the 1970s [110,111]. Experimentally, there has been renewed interest in this 
technique showing a beneficial effect on graft function when compared to CS and HMP 
techniques [112,113]. 
Hyperbaric oxygenation is the delivery of oxygen under increased atmospheric pressure. 
Hyperbaric oxygenation is normally used to treat decompression sickness, carbon monoxide 
poisoning, gas embolism, circulatory disorders and to promote wound healing [114-116]. 
However, it has been used in organ preservation. Under normal atmospheric pressure there 
is a limit to the amount of oxygen that can be carried in the blood. Increasing the 
atmospheric pressure at which it is delivered, increases the amount of dissolved oxygen in 
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the plasma allowing deeper penetration into the tissue (Henry’s Law). Therefore, tissues can 
be adequately oxygenated in the absence of a blood flow, a particular advantage in organ 
preservation [114,115]. Although an interesting concept and benefits have been 
demonstrated in liver and bowel transplantation, there has been little evidence of its use in 
kidney preservation in recent times. 
Oxygen can also be added during HMP. At present, HMP is not supplemented with oxygen 
based on the presumption that air equilibration in perfusates sufficiently supports energy 
metabolism and that oxygen consumption at 4ºC is around 5% of that found at body 
temperature [117]. However, ATP can be restored in part, with the addition of oxygen and 
energy substrates during perfusion [118]. Short periods of oxygenated perfusion after CS 
have also been used to resuscitate and condition organs, correcting ATP loss, reducing 
levels of oxidative stress and improving organ viability [119]. The addition of free radial 
scavengers such as superoxide dismutase (SOD) to the preservation solution has been found 
to be beneficial [119,120] in preventing the generation of oxygen free radicals in this highly 
oxygenated environment. 
20. Oxygenated solutions 
Oxygen can also be effectively administered during preservation by the use of artificial 
oxygen carriers. Perfluorocarbons (PFC) are inert solutions that have a high capacity for 
dissolving oxygen. They release oxygen down a concentration gradient creating a highly 
oxygenated environment which is not affected by temperature [121,122]. They can be added 
simply during CS in a technique called the two layer method (TLM). The density of the PFC 
allows two layers to be formed, PFC on the bottom and the preservation solution on top. 
The organ is placed in the solution and remains between the two layers. Oxygen can be 
continuously added allowing adequate diffusion through the organ. TLM has been 
particularly beneficial for pancreas preservation, allowing a sufficient amount of ATP to be 
generated to improve organ viability [121,123]. The use of TLM has shown potential in other 
organs but has failed to gain much support as the ability of oxygen to penetrate deep into 
tissue in more densely capsulated organs has been questioned. In the kidney its beneficial 
effect was found in a rat model, however, when applied in a porcine model the results 
showed no advantage [121,124-126].  
PFC can also be formulated as an emulsion for continuous perfusion and was applied 
during early attempts at machine perfusion [126-129]. However, the instability and adverse 
effects of the emulsions at that time prevented their continued application [121].  
Other novel oxygen carriers have recently been applied experimentally in kidney 
preservation. Hemarina-M101 (M101] is a respiratory pigment derived from a marine 
invertebrate, Arenicola marina [130]. It has an extremely high affinity for oxygen and 
functions over a large range of temperatures (4-37ºC) releasing oxygen against a gradient. 
Using a porcine kidney model Thuiller et al recently showed in that adding M101 to UW or 
HTK solution during CS for 24 hours improved renal function and reduced fibrosis after 
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transplantation. Micro-bubbles derived from Dodecafluoropentane (DDFPe) are also being 
investigated as oxygen replacement therapies and may in the future be applied during 
organ preservation [131,132].  
In addition to hypothermic conditions, perfluorochemical and haemoglobin solutions can 
also be used to deliver oxygen at normothermic temperatures [133]. Brasile et al originally 
developed an acellular normothermic solution based on a modified cell culture medium and 
PFC emulsion (Perflubron) [134]. The perfusate was made up of a highly enriched tissue 
culture-like medium containing essential and non-essential amino acids, lipids, 
carbohydrates. 
Historically, haemoglobin based solutions such as Stroma-free haemoglobin failed to 
demonstrate benefit experimentally because of toxic effects on the kidney. However, a 
newly developed solution, pyridoxalated haemoglobin-polyoxyethylene (PHP) has been 
deemed to be a more stable solution [133]. New more stable 2nd and 3rd generation PFCs are 
being developed and several are undergoing clinical trials to assess their safety. Humphreys 
et al recently used a commercially made PFC ‘Oxygent’ to provide oxygenation and reduced 
ischaemic injury to the kidney during a period of warm ischaemia by retrograde infusion 
through the urinary collecting system [135].  
Other solutions such as Lifor, a new artificial preservation medium containing a non protein 
oxygen carrier that can be used at room temperature may also be used for preservation [136, 
137]. These new solutions may hold more promise for future development of normothermic 
preservation perfusates. Nonetheless, the use of these normothermic perfusates in clinical 
practice is still awaited. 
21. Experimental agents 
I/R injury involves a cascade of events centralised by activated endothelial cells immediately 
after transplantation. One of the first inflammatory responses is the infiltration of 
neutrophils into the tissue. Cell adhesion molecules are recognised by leukocytes which 
interact with tissue cells to allow the movement of immune cells and mediators to the injury 
site [138,139]. This is mainly mediated through the up-regulation of endothelial adhesion 
molecules (ICAM-1, VCAM-1 and E-Selectin) [138]. The release of pro-inflammatory 
cytokines and chemokines, activation of the complement system and production of reactive 
oxygen species (ROS) [139] also cause significant cellular injury.  
A vast number of therapies have been investigated to ameliorate the detrimental effects of 
I/R injury such as vasodilatory agents [140,141], antioxidants [142-144], anti-inflammatory 
agents [145,146] and growth factors [147] and in the experimental setting many of these have 
proved beneficial. Of particular interest are the therapies that collectively target several 
mechanisms of I/R injury, these include the endogenous gaseous molecules nitric oxide 
(NO) [148,149], carbon monoxide (CO) [150,151] and hydrogen sulphide (H2S) [152,153]. 
Experimental models have shown their ability to reduce inflammation, oxidative damage, 
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apoptosis and promote smooth muscle relaxation causing vasodilation to enhance renal 
blood flow. However, their application into clinical practice is awaited. 
There is no single agent used as standard clinical practice to treat I/R injury and reduce 
DGF. Nonetheless, there are several agents of interest that have recently been examined in 
clinical trials. Recombinant human erythropoietin (EPO) is a treatment for anaemia in renal 
patients however it also has cytoprotective properties and has been shown to protect against 
kidney injury in experimental models [154, 155]. However, the results from two clinical 
trials contradict the majority of animal studies and showed no benefit of EPO in reducing 
rates of DGF [156,157]. Furthermore, in one trial concerns of the increase in the incidence of 
graft thrombosis where raised [157]. Other trials to assess the effects of EPO are ongoing and 
the results are pending. It has been suggested that EPO mediates protection through a tissue 
receptor that is distinct from the classical EPO-receptor that is known to mediate 
erythropoiesis [158]. A new compound has been formulated, pyroglutamate helix B surface 
peptide (pHBSP) that has the tissue-protective properties similar to those of EPO but 
without causing erythropoiesis [158]. Early experimental models suggest that this agent is 
beneficial in reducing kidney injury and may hold promise for future clinical trials.  
Several volatile anaesthetic agents sevoflurane and desflurane are also being trialled in 
clinical transplantation to reduce kidney injury. These agents are thought to have a 
conditioning effect that up-regulates protective mechanisms to reduce the I/R injury 
response [159]. The conditioning effect can also be applied by short intervals of ischaemia 
either directly to the organ or remotely to a limb [160]. It can be applied to the donor or 
recipient and again experimental models have shown the benefits of conditioning 
techniques. They are particularly attractive for clinical transplantation in that no 
pharmacological intervention is required and therefore the technique is expected to have a 
high safety profile. The results of several clinical trials are eagerly awaited. Propofol is 
another anaesthetic agent that may reduce I/R injury [161,162]. Experimental models have 
highlighted the anti-oxidant and anti-apoptotic properties of the agent [161,162].  
There has been a great deal of emphasis on stem cell therapy to reduce kidney injury. The 
ability of stem cells to differentiate into multiple lineages with the capacity to stimulate the 
regeneration of renal tissue is particularly attractive in kidney transplantation. Bone marrow 
derived mesenchymal stem cells have been used in the rat kidney to reduce inflammation 
and oxidative damage [163-165]. However, there has been no clinical application of this 
therapy in kidney transplantation. 
Immunosuppressant therapies used on induction can be used to reduce I/R injury and DGF. 
They suppress leukocyte infiltration and reduce endothelial injury. Anti-CD25 [166] and 
antithymocyte globulin (ATG) [167] are amongst some of the agents being currently being 
studied to reduce the incidence of DGF. 
22. Conclusion 
CI injury is detrimental to early graft function and as such early graft dysfunction is 
associated with reduced graft survival and complications after transplantation. However, 
 
Cold Ischaemic Injury in Kidney Transplantation 231 
the direct impact of CI on long term graft survival is less clear. Clinical studies suggest that 
CI may not necessarily be an independent risk factor for reduced graft survival. 
Nonetheless, further evidence is needed to examine the relationship between CI injury and 
graft survival. Hypothermic preservation techniques are designed to counteract the 
detrimental effect of CI injury and hypothermic machine perfusion is emerging as a superior 
method of preservation compared with static cold storage. Other preservation techniques 
are being developed such as normothermic perfusion and the addition of oxygen and 
oxygen carriers during hypothermic preservation. These techniques may hold promise for 
the future to limit the damage caused by CI injury. Therapeutic agents administered to the 
recipient may also prove beneficial in reducing early graft dysfunction. Nonetheless, 
translation of these therapies from animal models to clinical practice remains difficult and 
the search for the optimal agent or therapy is ongoing. 
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